To further assess the binding stability of the apigenin-AKT1 complex, a 100 ns MDS was performed, which confirmed the structural stability.<h4>Conclusion</h4>Apigenin and kaempferol showed potential as dual-targeting agents for colon cancer therapy. This evidence concerns the gene AKT1 and malignant colon neoplasm.